Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Location: United States, California, San Diego
Employees: 201-500
Total raised: $76.5M
Founded date: 1983
Investors 1
| Date | Name | Website |
| - | Savitr Cap... | savitrcapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.08.2022 | - | $76.5M | - |
Mentions in press and media 22
| Date | Title | Description |
| 17.04.2023 | Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference | SAN DIEGO, April 17, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet ... |
| 16.09.2022 | Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) | - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for PONV - - Delivered via a single 30-second IV injection, APONVIE has demonstrated rapid achievement of therape... |
| 18.11.2021 | Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA | SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importa... |
| 12.11.2021 | Heron Therapeutics to Present at Upcoming Investor Conferences | SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importa... |
| 03.11.2021 | Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates | SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan... |
| 28.10.2021 | Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021 | SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importa... |
| 04.10.2021 | Heron Therapeutics : Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting | SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan... |
| 21.09.2021 | Heron Therapeutics : to Present at the 2021 Cantor Virtual Global Healthcare Conference | SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most import... |
| 09.08.2021 | Heron Therapeutics : Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates | SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan... |
| 28.07.2021 | Heron Therapeutics : Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patient... | SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importa... |
Show more